An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs ABC 294640 (Primary)
- Indications Diffuse large B cell lymphoma; Kaposi's sarcoma
- Focus Adverse reactions
- Sponsors Apogee Biotechnology Corporation; RedHill Biopharma
- 05 Dec 2017 Planned initiation date changed from 1 Apr 2015 to 1 Jul 2014.
- 05 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 10 Jun 2017 Biomarkers information updated